In a TNBC mouse model, enhanced anti-tumor efficacy was observed when the combination treatment was administered, as evidenced by increased intra-tumoral recruitment and activation of CD8+ T cells, along with a reduction in the immunosuppressive function of polymorphonuclear-MDSCs (PMN-MDSCs). The gene discussed is CD8A; the disease is neoplasm.